XBP1 and Miyoshi myopathy: While the precise mechanism underlying how XBP1s influence the expression of RANKL requires further elucidation, targeting the blockade of the IRE1α‐XBP1 pathway may be a potential therapy strategy for wear particles‐induced osteolysis and MM.